SRR5088895
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.500
- E2F_TARGETS+0.400
- MYC_TARGETS_V1+0.400
- DNA_REPAIR+0.300
- OXIDATIVE_PHOSPHORYLATION+0.300
- UNFOLDED_PROTEIN_RESPONSE+0.300
- CHOLESTEROL_HOMEOSTASIS+0.200
- G2M_CHECKPOINT+0.200
- GLYCOLYSIS+0.200
- MITOTIC_SPINDLE+0.200
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.600
- INTERFERON_GAMMA_RESPONSE-0.600
- ALLOGRAFT_REJECTION-0.500
- IL6_JAK_STAT3_SIGNALING-0.500
- INFLAMMATORY_RESPONSE-0.500
- KRAS_SIGNALING_UP-0.500
- COMPLEMENT-0.400
- TNFA_SIGNALING_VIA_NFKB-0.400
- ANGIOGENESIS-0.300
- COAGULATION-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR5088894 | — | — | 0.959 |
| 2 | SRR6013533 | — | cohortSQ2 | 0.924 |
| 3 | SRR2780123 | — | — | 0.899 |
| 4 | 20120209.TNBC | — | E | 0.898 |
| 5 | SAMN03290931 | — | — | 0.897 |
| 6 | SRR10899994 | — | — | 0.891 |
| 7 | SRR12696795 | — | — | 0.888 |
| 8 | TCGA-22-A5C4-01A-12R-A27Q-07 | — | cohortSQ1 | 0.888 |
| 9 | dfc53815-0784-48c7-84aa-f23d087a13df | — | — | 0.887 |
| 10 | 236350e9-8964-42ae-8880-d2f2281ff993 | — | — | 0.886 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |